Sage Journals: Discover world-class research

Abstract

Keywords

rituximab pemphigus

Get full access to this article

View all access options for this article.

References

Hammers

CM.

Chen

Lin

et al. Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol. 2015;135(3):742-749.doi:10.1038/jid.2014.291

http://www.ncbi.nlm.nih.gov/pubmed/25142730

Kushner

CJ.

Wang

Tovanabutra

Tsai

DE.

Werth

VP.

Payne

. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404.doi:10.1001/jamadermatol.2019.3236

http://www.ncbi.nlm.nih.gov/pubmed/31642878

Murrell

DF.

Dick

Ahmed

et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046.doi:10.1016/j.jaad.2008.01.012

http://www.ncbi.nlm.nih.gov/pubmed/18339444

Valiathan

Ashman

Asthana

. Effects of ageing on the immune system: infants to elderly. Scand J Immunol. 2016;83(4):255-266.doi:10.1111/sji.12413

http://www.ncbi.nlm.nih.gov/pubmed/26808160

Joly

Maho-Vaillant

Prost-Squarcioni

et al. First-Line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.doi:10.1016/S0140-6736(17)30070-3

http://www.ncbi.nlm.nih.gov/pubmed/28342637

Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris

Abstract

Keywords

Get full access to this article

References